[go: up one dir, main page]

PE20190417A1 - Uso de probioticos en el tratamiento y/o la prevencion de la dermatitis atopica - Google Patents

Uso de probioticos en el tratamiento y/o la prevencion de la dermatitis atopica

Info

Publication number
PE20190417A1
PE20190417A1 PE2019000223A PE2019000223A PE20190417A1 PE 20190417 A1 PE20190417 A1 PE 20190417A1 PE 2019000223 A PE2019000223 A PE 2019000223A PE 2019000223 A PE2019000223 A PE 2019000223A PE 20190417 A1 PE20190417 A1 PE 20190417A1
Authority
PE
Peru
Prior art keywords
prevention
treatment
atopic dermatitis
probiotics
lactis
Prior art date
Application number
PE2019000223A
Other languages
English (en)
Inventor
Lopez Vicente Manuel Navarro
Bosca Ana Adela Ramirez
Orquin Jose Manuel Perez
Vidal Daniel Ramon
Martinez Salvador Genoves
Cuadros Maria Empar Chenoll
Cortes Francisco Manuel Codoner
Original Assignee
Bionou Res S L
Korott S L
Biopolis SL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=56920674&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20190417(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bionou Res S L, Korott S L, Biopolis SL filed Critical Bionou Res S L
Publication of PE20190417A1 publication Critical patent/PE20190417A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/745—Bifidobacteria
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2200/00—Function of food ingredients
    • A23V2200/30—Foods, ingredients or supplements having a functional effect on health
    • A23V2200/32—Foods, ingredients or supplements having a functional effect on health having an effect on the health of the digestive tract
    • A23V2200/3204—Probiotics, living bacteria to be ingested for action in the digestive tract

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Nutrition Science (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Dairy Products (AREA)
  • Confectionery (AREA)
  • Preparation Of Fruits And Vegetables (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Meat, Egg Or Seafood Products (AREA)
  • Non-Alcoholic Beverages (AREA)

Abstract

Referido a una composicion probiotica que comprende Bifidobacterium animalis subs. lactis (B. lactis), Bifidobacterium longum y Lactobacillus casei; en particular, las cepas de B. lactis CECT 8145, B. longum CECT 7347 y/o L. rhamnosus casei CECT 9104. Tambien se refiere al uso en el tratamiento y/o la prevencion de la dermatitis atopica.
PE2019000223A 2016-07-18 2017-07-18 Uso de probioticos en el tratamiento y/o la prevencion de la dermatitis atopica PE20190417A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP16382342.0A EP3272396A1 (en) 2016-07-18 2016-07-18 Use of probiotics in the treatment and/or prevention of atopic dermatitis

Publications (1)

Publication Number Publication Date
PE20190417A1 true PE20190417A1 (es) 2019-03-19

Family

ID=56920674

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2019000223A PE20190417A1 (es) 2016-07-18 2017-07-18 Uso de probioticos en el tratamiento y/o la prevencion de la dermatitis atopica

Country Status (28)

Country Link
US (2) US20190282636A1 (es)
EP (2) EP3272396A1 (es)
JP (1) JP6998364B2 (es)
KR (1) KR102390806B1 (es)
CN (1) CN110214014B (es)
AR (1) AR109085A1 (es)
AU (1) AU2017299137B2 (es)
CA (1) CA3031002A1 (es)
DK (1) DK3484585T4 (es)
EA (1) EA201990086A1 (es)
ES (1) ES2863398T3 (es)
HR (1) HRP20210995T4 (es)
HU (1) HUE055264T2 (es)
IL (1) IL264282B2 (es)
MA (1) MA44893B1 (es)
MX (1) MX2019000821A (es)
MY (1) MY194858A (es)
PE (1) PE20190417A1 (es)
PH (1) PH12019500123B1 (es)
PL (1) PL3484585T5 (es)
PT (1) PT3484585T (es)
RS (1) RS62079B1 (es)
RU (1) RU2757453C2 (es)
SA (1) SA519400920B1 (es)
SI (1) SI3484585T2 (es)
UA (1) UA126664C2 (es)
WO (1) WO2018015388A1 (es)
ZA (1) ZA201900869B (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109652349B (zh) * 2019-02-25 2021-03-02 江南大学 一株能够缓解特应性皮炎的长双歧杆菌及其应用
KR102136346B1 (ko) * 2019-12-23 2020-07-22 주식회사 락토메이슨 한국인 영유아 유래 신규한 비피도박테리움 애니멀리스 락티스 lm1017을 유효성분으로 포함하는, 아토피 피부염의 예방 및 치료용 조성물
EP3851115A1 (en) 2020-01-15 2021-07-21 Biopolis, S.L. Probiotic composition for its use as an antioxidant
CN111296842B (zh) * 2020-02-14 2021-01-05 赵一鸣 一种具有抗敏作用的益生菌组合物
CN111528479A (zh) * 2020-05-15 2020-08-14 深圳爱米基因科技有限责任公司 一种缓解特应性皮炎功能的益生菌和益生元组合物及应用
EP3915537A1 (en) * 2020-05-28 2021-12-01 DuPont Nutrition Biosciences ApS Bifidobacteria for preventing, reducing or treating skin aging
EP3973971B1 (de) * 2020-09-28 2025-12-31 INSTITUT ALLERGOSAN Holding GmbH Probiotische pharmazeutische zusammensetzung
CN113430133B (zh) * 2021-06-24 2023-06-23 微康益生菌(苏州)股份有限公司 一种能够缓解溃疡性结肠炎的复合益生菌、制备方法及其应用
DK4429686T3 (da) * 2021-12-16 2025-08-18 Biopolis SL Postbiotiske sammensætninger omfattende b. longum cect- 7347 og l. rhamnosus cect- 8361 og terapeutiske anvendelser deraf
KR102880991B1 (ko) * 2021-12-17 2025-11-03 박선민 뮤신 분해능을 갖는 혼합 균주 및 그의 용도

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004250337A (ja) * 2003-02-18 2004-09-09 Sunstar Inc アレルギー疾患改善用製剤
MX2007004135A (es) * 2004-10-04 2007-06-15 Oreal Composicion cosmetica y/o dermatologica para pieles sensibles.
CN101165162A (zh) * 2007-09-30 2008-04-23 苏国权 一种益生菌活性制剂
ES2343499B1 (es) * 2007-12-24 2011-06-10 Consejo Superior De Investigaciones Cientificas Microorganismos para mejorar el estado de salud de individuos con desordenes relacionados con la ingesta de gluten.
ES2559008T3 (es) * 2009-05-11 2016-02-10 Nestec S.A. Bifidobacterium longum NCC2705 no replicante y trastornos inmunitarios
EP2251020A1 (en) * 2009-05-11 2010-11-17 Nestec S.A. Short-time high temperature treatment generates microbial preparations with anti-inflammatory profiles
EP2228067B1 (de) * 2010-02-22 2013-12-11 LR Health & Beauty Systems GmbH Probiotische Zusammensetzung und deren Verwendung
ES2389547B1 (es) * 2010-12-07 2013-08-08 Consejo Superior De Investigaciones Científicas (Csic) Bifidobacterium cect 7765 y su uso en la prevención y/o tratamiento del sobrepeso, la obesidad y patologías asociadas.
KR20130049554A (ko) * 2011-11-04 2013-05-14 주식회사 쎌바이오텍 아토피 예방 또는 치료용 조성물
ES2526986B1 (es) * 2013-07-18 2015-11-02 Biopolis, S.L. Nueva cepa de Bifidobacterium animalis subsp. lactis CECT 8145 y su uso para el tratamiento y/o prevención de sobrepeso y obesidad y enfermedades asociadas
CN104605277A (zh) * 2013-11-05 2015-05-13 熊涛 一种功能性益生菌发酵果蔬粉的制备方法
KR101545551B1 (ko) * 2013-12-12 2015-08-19 주식회사한국야쿠르트 인슐린 저항성 개선 효능을 갖는 7종의 유산균 복합균주를 유효성분으로 함유하는 조성물
CN103705543A (zh) * 2013-12-25 2014-04-09 广州华农大实验兽药有限公司 一种动物用粪源复方益生菌可溶性粉及其制备方法
KR101724601B1 (ko) * 2014-11-04 2017-04-10 주식회사 쎌바이오텍 아토피 예방 또는 치료용 조성물

Also Published As

Publication number Publication date
PH12019500123A1 (en) 2019-04-15
MA44893A1 (fr) 2019-05-31
MA44893B1 (fr) 2021-06-30
MX2019000821A (es) 2019-12-16
AU2017299137B2 (en) 2023-03-30
SI3484585T2 (sl) 2025-11-28
AR109085A1 (es) 2018-10-24
EP3272396A1 (en) 2018-01-24
NZ750450A (en) 2025-07-25
CN110214014B (zh) 2024-08-02
ES2863398T3 (es) 2021-10-11
JP6998364B2 (ja) 2022-01-18
PL3484585T3 (pl) 2021-11-22
KR20190042575A (ko) 2019-04-24
RU2019104462A3 (es) 2020-08-18
US20190282636A1 (en) 2019-09-19
CN110214014A (zh) 2019-09-06
WO2018015388A1 (en) 2018-01-25
CA3031002A1 (en) 2018-01-25
DK3484585T3 (da) 2021-06-21
PH12019500123B1 (en) 2024-02-02
HUE055264T2 (hu) 2021-11-29
PT3484585T (pt) 2021-06-11
RU2019104462A (ru) 2020-08-18
JP2019521174A (ja) 2019-07-25
AU2017299137A1 (en) 2019-02-28
SI3484585T1 (sl) 2021-08-31
EA201990086A1 (ru) 2019-12-30
IL264282A (en) 2019-02-28
RS62079B1 (sr) 2021-07-30
SA519400920B1 (ar) 2024-01-29
EP3484585A1 (en) 2019-05-22
RU2757453C2 (ru) 2021-10-15
EP3484585B2 (en) 2025-07-09
UA126664C2 (uk) 2023-01-11
DK3484585T4 (en) 2025-09-08
IL264282B2 (en) 2024-08-01
US20230048705A1 (en) 2023-02-16
HRP20210995T1 (hr) 2021-09-17
ZA201900869B (en) 2019-12-18
MY194858A (en) 2022-12-20
IL264282B1 (en) 2024-04-01
BR112019001116A2 (pt) 2019-04-30
HRP20210995T4 (hr) 2025-11-07
KR102390806B1 (ko) 2022-04-25
PL3484585T5 (pl) 2025-09-22
EP3484585B1 (en) 2021-03-24

Similar Documents

Publication Publication Date Title
PE20190417A1 (es) Uso de probioticos en el tratamiento y/o la prevencion de la dermatitis atopica
MX389112B (es) Uso de probioticos en el tratamiento y/o la prevencion de la enfermedad de la psoriasis.
MX2011012069A (es) Micro-organismos no-replicantes y su efecto inmuno estimulador.
ZA202105310B (en) Probiotic compositions comprising lactobacillus reuteri strains and methods of use
IT201600091033A1 (it) Ceppi di batteri probiotici appartenenti al genere Bifidobacterium e loro estratti di cellule probiotiche (ECP) aventi proprietà immunostimolanti.
DK3554517T3 (da) Probiotisk sammensætning omfattende lactobacillus rhamnosus og lactobacillus paracasei stammer
HRPK20130487B3 (hr) Formulacija probiotika s apigeninom i ekstraktom paprene metvice
CL2018001936A1 (es) Nueva cepa bacteriana probiótica de lactobacillus plantarum y composiciones y usos de la misma en el tratamiento de la inflamación.
EP3601525C0 (en) LACTOBACILLUS CASEI PROBIOTIC STRAIN AND ITS USES
MX2024006254A (es) Uso de postbioticos en el tratamiento y/o prevencion de los trastornos de ansiedad.
CL2017001706A1 (es) Empleo de probióticos en el incremento de la fertilidad masculina.
AR095486A1 (es) Composición nutricional para el tratamiento de emesis idiopática crónica en felinos y canes
CL2009001511A1 (es) Formulacion farmaceutica que comprende cepas viables de lactobacillus acidophilus lpv 31 y l. plantarum lpm-01, la cual es util en la prevencion y/o tratamiento de infecciones urinarias y en mejorar la respuesta inmune en pacientes inmunocopromentidos.
PL406051A1 (pl) Zastosowanie kompozycji probiotycznej
Tehrani et al. The effect of some lactobacillus species (probiotics) on biofilm inhibition in Enterococcus faecium
PL397178A1 (pl) Kompozycja probiotyczna
UA120331U (uk) Пробіотик "болмол"
UA89037U (uk) Кормова добавка з пробіотичною дією "пробіолакт"
HK40000927A (en) Novel probiotic bacterial strain of lactobacillus plantarum and compositions and uses thereof in the treatment of inflammation